KRAS and familial pancreatic carcinoma: Others noted improved prognosis for patients with pancreatic cancer with KRAS G12R mutations vs. alternative variants,6-8 but a comprehensive analysis of genomic, transcriptomic, or metabolic dependencies for oncogenic KRAS variants and correlations with clinical outcomes and therapeutic targeting has yet to be performed.